|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.70 HKD | +2.83% |
|
-6.48% | +9.77% |
| 01-12 | Innovent Biologics: a Rising Star in Biopharma |  |
| 12-31 | Wall Street Cues, Economic Outlooks Roil Asian Stock Markets | MT |
| Capitalization | 130B 145B 18.62B 15.83B 14.68B 13.72B 25.57B 1,711B 27.1B 168B 66.59B 808B 69.81B 68.39B 2,938B | P/E ratio 2025 * |
76.6x | P/E ratio 2026 * | 40.2x |
|---|---|---|---|---|---|
| Enterprise value | 120B 134B 17.21B 14.64B 13.57B 12.68B 23.63B 1,581B 25.05B 155B 61.55B 746B 64.53B 63.21B 2,715B | EV / Sales 2025 * |
9.12x | EV / Sales 2026 * | 6.78x |
| Free-Float |
93.21% | Yield 2025 * |
-
| Yield 2026 * | 0.02% |
Last Transcript: Innovent Biologics, Inc.
| 1 day | +2.83% | ||
| 1 week | -6.48% | ||
| Current month | +9.77% | ||
| 1 month | +3.72% | ||
| 3 months | -1.65% | ||
| 6 months | -4.89% | ||
| Current year | +9.77% |
| 1 week | 80.45 |  | 89.35 |
| 1 month | 76 | | 92.75 |
| Current year | 76.75 | | 92.75 |
| 1 year | 31.3 | | 109.1 |
| 3 years | 27.3 | | 109.1 |
| 5 years | 18.06 | | 109.1 |
| 10 years | 14 | | 109.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
De Chao Yu
CEO | Chief Executive Officer | 62 | 28/04/2011 |
Fei You
DFI | Director of Finance/CFO | 47 | 05/02/2024 |
Ghang Shou Gao
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 77 | 26/08/2025 |
Gary Zieziula
BRD | Director/Board Member | 71 | 31/05/2022 |
Charles Cooney
BRD | Director/Board Member | 81 | 18/10/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.83% | -6.48% | +164.45% | +94.20% | 18.62B | |
| -0.26% | +2.80% | +8.48% | +3.24% | 77.31B | |
| +0.68% | +2.33% | -33.47% | -39.80% | 59.49B | |
| -0.58% | -3.09% | +40.04% | +234.20% | 57.5B | |
| +1.35% | +80.20% | +80.20% | +80.20% | 56.95B | |
| -1.27% | +4.36% | +19.43% | -41.22% | 25.17B | |
| -2.92% | -3.97% | +40.62% | +22.17% | 20.02B | |
| -6.09% | +16.45% | +14.91% | -75.27% | 19.03B | |
| -2.55% | +2.11% | +109.95% | +813.97% | 15.01B | |
| -0.04% | -.--% | +3.78% | +171.73% | 14.02B | |
| Average | -0.88% | +0.71% | +44.84% | +126.34% | 36.31B | |
| Weighted average by Cap. | -0.35% | +0.13% | +32.73% | +83.35% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.14B 14.72B 1.89B 1.61B 1.49B 1.39B 2.59B 173B 2.75B 17.01B 6.75B 81.88B 7.08B 6.93B 298B | 17.29B 19.37B 2.48B 2.11B 1.96B 1.83B 3.41B 228B 3.62B 22.38B 8.88B 108B 9.31B 9.12B 392B |
| Net income | 1.66B 1.86B 239M 203M 188M 176M 328M 21.94B 348M 2.15B 854M 10.36B 896M 877M 37.69B | 3.19B 3.57B 458M 389M 361M 337M 629M 42.07B 667M 4.13B 1.64B 19.87B 1.72B 1.68B 72.26B |
| Net Debt | -9.82B -11B -1.41B -1.2B -1.11B -1.04B -1.94B -130B -2.05B -12.7B -5.04B -61.17B -5.29B -5.18B -223B | -12.37B -13.86B -1.78B -1.51B -1.4B -1.31B -2.44B -163B -2.59B -16.01B -6.36B -77.08B -6.66B -6.53B -280B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 83.70 $ | +2.83% | 12,098,340 |
| 22/01/26 | 81.40 $ | -1.57% | 11,677,210 |
| 21/01/26 | 82.70 $ | -0.60% | 9,690,567 |
| 20/01/26 | 83.20 $ | -2.52% | 9,115,621 |
| 19/01/26 | 85.35 $ | -4.64% | 14,220,210 |
Delayed Quote Hong Kong S.E., January 23, 2026 at 04:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1801 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition